Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 8/20 | 0.53 |
| ▸ | AKT2 | P31751 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18662857 | 0.97 | AKT1 (0.50) | AKT1AKT2ALDH1A1MAPTCA1 | |
| SCHEMBL871865 | 0.93 | CA1 (0.52) | AKT1AKT2ALDH1A1MAPTCA1 | |
| Hydrochloric Acid SCHEMBL871688 | 0.91 | CA1 (0.50) | AKT1AKT2ALDH1A1MAPTCA1 | |
| SCHEMBL2109932 | 0.87 | STS (0.49) | AKT1AKT2ALDH1A1MAPTCA1 | |
| SCHEMBL19331211 | 0.85 | ALDH1A1 (0.50) | AKT1AKT2ALDH1A1MAPTCA1 | |
| SCHEMBL19343523 | 0.81 | NPC1 (0.48) | ALDH1A1MAPTCA1CA2TDP1 | |
| SCHEMBL14292182 | 0.81 | AKT1 (0.49) | AKT1AKT2ALDH1A1LOXL2TSHR | |
| SCHEMBL31237031 | 0.81 | AKT1 (0.49) | AKT1AKT2ALDH1A1LOXL2TSHR | |
| SCHEMBL28670569 | 0.81 | CA1 (0.50) | ALDH1A1MAPTCA1CA2TDP1 | |
| SCHEMBL19343552 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTCA1CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| EP-4116291-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCERS AND INFLAMMATIONS | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-113354585-A | Synthesis of novel EP4 antagonists and their use in cancer and inflammation | 湖北生物医药产业技术研究院有限公司 | 2021-09-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | AKT1 2730/4885AKT2 1900/4885ALDH1A1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.